HomeAgeX Therapeutics

AgeX Therapeutics

AgeX Therapeutics Licensee ImStem Biotechnology Announces FDA Lifted the Hold and Cleared the Investigational New Drug Application for IMS001 for the Treatment of Multiple Sclerosis

Today Agex announced that ImStem Biotechnology, Inc., a biopharmaceutical company pioneering the development of mesenchymal stem cells (hES-MSC) derived from human embryonic stem cells has received notification from the U.S. Food and Drug Administration (FDA) that it has lifted the hold and cleared the Investigational New Drug (IND) application to evaluate IMS001 for the treatment of multiple sclerosis (MS). IMS001 was derived from the pluripotential cell line designated ESI-053 licensed from AgeX.

Agex Therapeutics CEO Dr. Michael D. West to Present at Three Conferences in March 2018 

March 01, 2018 08:00 AM Eastern Standard Time ALAMEDA, Calif.–(BUSINESS WIRE)–AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE American: BTX) today announced that the company’s Chief Executive Officer Michael D. West, Ph.D. will participate at three upcoming...